TC BioPharm Holdings ^{Priced, Nasdaq: TCBP}

TCB based in Scotland, is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled TCB to develop a range of clinical-stage cell therapies designed to combat identified cancers and viral infections. TCB is embarking on phase II-into-pivotal (phase III) clinical studies, which are expected to commence in the fourth quarter of 2021, following United Kingdom and European Union regulations, with a view to launching its first oncology product, which will be for the treatment of acute myeloid leukemia (abbreviated as AML). The Company plans to conduct similar clinical trials in the United States in 2022 for the treatment of AML following an application to the FDA in H1 2022. Clinical results generated thus far have enabled TCB to obtain FDA orphan drug status for its method of treatment of AML. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, TCB is also developing an innovative range of genetically modified chimeric antigen receptor modified T cell (abbreviated as CAR-T) products for treatment of solid cancers. TCB believes that solid cancers are more difficult to treat than blood cancers and may require addition of a chimeric antigen receptor.